On Jan. 9, 2012, the U.S. Food and Drug Administration (FDA) issued a draft guidance document to assist industry in developing new formulations of opioid drugs with that makes it more difficult to abuse them: “Guidance for Industry: Abuse-Deterrent Opioids—Evaluation and Labeling.” Abuse-deterrent formulations target the known or expected routes of abuse, such as crushing in order to snort or dissolving in order to inject, for the specific opioid drug substance in that formulation. Read more.